Skip to content
CSE: XRX.CN 0.20 0.00 0.00%  
XORTX
  • About
    • Management Team
    • Board of Directors
    • Advisory Board
  • Pipeline
    • Autosomal Dominant Polycystic Kidney Disease
    • Diabetic Nephropathy
    • Metabolic Syndrome / Diabetes
    • Hypertension
  • Strategic Partnerships
  • Investors
    • Press Releases
    • Presentations
    • Financials
    • SEDAR
    • Transfer Agent
    • Upcoming Events
  • Contact
Site Search

pipeline-1024px-wide

pipeline-1024px-wide

Press Releases

  • XORTX Shares Findings of Diabetes Study in Youths Supporting High Uric Acid Advances Kidney Disease Progression April 16, 2019
  • XORTX Shares Findings of New Diabetes Study Supporting Uric Acid as an Independent Risk Factor March 25, 2019
  • XORTX Signs LOI for Co-Development and Licensing Agreement with Japan’s Teijin Pharma Limited March 12, 2019
  • XORTX to Present at NobleConXV Noble Capital Markets’ 15th Annual Investor Conference January 28, 2019
  • XORTX Receives FDA Response on Orphan Drug Designation Application November 26, 2018
XORTX Therapeutics Inc.
4000, 421 7th Avenue SW
Calgary, Alberta T2P 4K9
Ph: +1 (403) 455-7727
info@xortx.com
Theme by Colorlib Powered by WordPress